Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021
PHIOW
PHIOW was delisted on the 21st of December, 2021.
2 hedge funds and large institutions have $0 invested in Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
100% less capital invested
Capital invested by funds: $1K → $0 (-$1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$289 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | +$289 | +1,664 | New |
|
PHIOW Hedge Fund Activity: Q3 2021 in Review
2 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 (PHIOW) for Q3 2021, worth a combined $0 — down 100% from $1K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PHIOW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $289.
- 2 institutional investors held Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 (PHIOW) as of Q3 2021, up from 1 in Q2 2021.
- Funds reported $0 of Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 stock for Q3 2021, down 100% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 positions in Q3 2021 and 0 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021 buyer in Q3 2021 was UBS Group, an estimated $289 added.
Based on aggregated 13F filings for Q3 2021.